Shanghai Fosun Pharmaceutical (Group) Co (HKSE:02196) Cyclically Adjusted Revenue per Share: HK$9.03 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02196 Shanghai Fosun Pharmaceutical (Group) Co Ltd HKSE:02196
91 GF Score
Price HK$16.14
GF Value HK$19.11
Valuation Modestly Undervalued
! 10 Warning Signs
View Full Analysis

What is Shanghai Fosun Pharmaceutical (Group) Co Cyclically Adjusted Revenue per Share?

Shanghai Fosun Pharmaceutical (Group) Co HKSE:02196 +1.96% 91 Cyclically Adjusted Revenue per Share is HK$9.03 as of Jun. 2026. GuruFocus rates HKSE:02196 with a GF Score™ of 91/100 and a GF Value™ of HK$19.11 (Modestly Undervalued). The stock has 10 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Shanghai Fosun Pharmaceutical (Group) Co's adjusted revenue per share for the three months ended in Jun. 2026 was HK$4.512. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is HK$9.03 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Shanghai Fosun Pharmaceutical (Group) Co's average Cyclically Adjusted Revenue Growth Rate was 8.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 11.60% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 14.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Shanghai Fosun Pharmaceutical (Group) Co was 17.20% per year. The lowest was 9.00% per year. And the median was 12.55% per year.

As of today (2026-09-03), Shanghai Fosun Pharmaceutical (Group) Co's current stock price is HK$16.14. Shanghai Fosun Pharmaceutical (Group) Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was HK$9.03. Shanghai Fosun Pharmaceutical (Group) Co's Cyclically Adjusted PS Ratio of today is 1.79.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Shanghai Fosun Pharmaceutical (Group) Co was 10.49. The lowest was 1.60. And the median was 4.58.


Shanghai Fosun Pharmaceutical (Group) Co  (HKSE:02196) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Shanghai Fosun Pharmaceutical (Group) Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=16.14/9.03
=1.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Shanghai Fosun Pharmaceutical (Group) Co was 10.49. The lowest was 1.60. And the median was 4.58.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Shanghai Fosun Pharmaceutical (Group) Co Cyclically Adjusted Revenue per Share Related Terms


Shanghai Fosun Pharmaceutical (Group) Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Shanghai Fosun Pharmaceutical (Group) Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Fosun Pharmaceutical (Group) Co Cyclically Adjusted Revenue per Share Chart

Shanghai Fosun Pharmaceutical (Group) Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.07 7.11 7.46 6.76 9.57

Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.32 10.92 9.57 9.86 9.03

HKSE:02196 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fosun Pharmaceutical (Group) Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Fosun Pharmaceutical (Group) Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai Fosun Pharmaceutical (Group) Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Shanghai Fosun Pharmaceutical (Group) Co's Cyclically Adjusted PS Ratio falls into.


HKSE:02196
91GF Score
Shanghai Fosun Pharmaceutical (Group) Co Ltd HKSE:02196
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Fosun Pharmaceutical (Group) Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Shanghai Fosun Pharmaceutical (Group) Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=4.512/116.0564*116.0564
=4.512

Current CPI (Jun. 2026) = 116.0564.

Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.845 102.400 2.091
201612 1.860 102.600 2.104
201703 1.837 103.200 2.066
201706 2.033 103.100 2.288
201709 2.176 104.100 2.426
201712 2.632 104.500 2.923
201803 2.816 105.300 3.104
201806 3.063 104.900 3.389
201809 2.692 106.600 2.931
201812 3.014 106.500 3.284
201903 3.094 107.700 3.334
201906 3.253 107.700 3.505
201909 3.122 109.800 3.300
201912 3.177 111.200 3.316
202003 2.592 112.300 2.679
202006 3.418 110.400 3.593
202009 3.607 111.700 3.748
202012 3.772 111.500 3.926
202103 3.743 112.662 3.856
202106 4.213 111.769 4.375
202109 4.724 112.215 4.886
202112 5.788 113.108 5.939
202203 5.048 114.335 5.124
202206 4.976 114.558 5.041
202209 4.326 115.339 4.353
202212 5.174 115.116 5.216
202303 4.642 115.116 4.680
202306 4.363 114.558 4.420
202309 3.627 115.339 3.650
202312 4.239 114.781 4.286
202403 4.162 115.227 4.192
202406 4.149 114.781 4.195
202409 4.234 115.785 4.244
202412 4.153 114.893 4.195
202503 3.830 115.116 3.861
202506 4.115 114.907 4.156
202509 4.074 115.471 4.095
202512 5.119 115.832 5.129
202603 4.335 116.303 4.326
202606 4.512 116.056 4.512

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of HK$9.03 mean?
Shanghai Fosun Pharmaceutical (Group) Co (HKSE:02196) has a Cyclically Adjusted Revenue per Share of HK$9.03 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors.
Is Shanghai Fosun Pharmaceutical (Group) Co's Cyclically Adjusted Revenue per Share too high?
Shanghai Fosun Pharmaceutical (Group) Co's current Cyclically Adjusted Revenue per Share is HK$9.03. Overall, Shanghai Fosun Pharmaceutical (Group) Co has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fosun Pharmaceutical (Group) Co's Cyclically Adjusted Revenue per Share compare to ZTS?
Shanghai Fosun Pharmaceutical (Group) Co's Cyclically Adjusted Revenue per Share of HK$9.03 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors. Shanghai Fosun Pharmaceutical (Group) Co's current Cyclically Adjusted Revenue per Share is HK$9.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fosun Pharmaceutical (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co (HKSE:02196) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$19.11, compared to a current price of HK$16.14 — trading 15.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is HK$9.03. Shanghai Fosun Pharmaceutical (Group) Co's overall GF Score™ is 91/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Shanghai Fosun Pharmaceutical (Group) Co (HKSE:02196), the current Cyclically Adjusted Revenue per Share is HK$9.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Fosun Pharmaceutical (Group) Co (HKSE:02196) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co stock appears to be undervalued. The current stock price of HK$16.14 is trading 15.5% below its estimated GF Value™ of HK$19.11. GuruFocus considers Shanghai Fosun Pharmaceutical (Group) Co to be Modestly Undervalued.

Key valuation signals for HKSE:02196:

  • Cyclically Adjusted Revenue per Share: HK$9.03
  • GF Value™: HK$19.11 vs. price of HK$16.14 (15.5% below fair value)
  • GF Score™: 91/100 with 10 warning signs

No single metric tells the full story. See the HKSE:02196 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shanghai Fosun Pharmaceutical (Group) Co Business Description

Address No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
91GF Score

Get the complete analysis for HKSE:02196

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$16.14
Price
HK$19.11
GF Value